Primary source: View
Translated From French
PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.
PRAC has initiated a safety review of injectable iron-containing medicines, which may influence future regulatory actions and safety assessments.
This safety review could lead to new regulatory requirements or updates regarding the use and monitoring of injectable iron products, impacting patient safety and industry practices.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Regulatory Intelligence Lead
Ongoing monitoring is required as new updates emerge from PRAC.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
In its recent meeting, PRAC started a safety review focused on injectable iron-containing medicines, following ongoing safety signals associated with these products. This action indicates potential regulatory implications for involved stakeholders.
What changed: PRAC has initiated a safety review of injectable iron-containing medicines, which may influence future regulatory actions and safety assessments.
Why it matters: This safety review could lead to new regulatory requirements or updates regarding the use and monitoring of injectable iron products, impacting patient safety and industry practices.
Practical implication: Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.
Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
Regulatory intelligence processes must update reporting timelines and workflows to incorporate the new PSUSA findings for exemestane.
